Aligos Therapeutics Statistics
Share Statistics
Aligos Therapeutics has 3.59M shares outstanding. The number of shares has increased by -84.74% in one year.
| Shares Outstanding | 3.59M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -91.78% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.67M |
| Failed to Deliver (FTD) Shares | 5.93K |
| FTD / Avg. Volume | 1.81% |
Short Selling Information
The latest short interest is 121.30K, so 3.38% of the outstanding shares have been sold short.
| Short Interest | 121.30K |
| Short % of Shares Out | 3.38% |
| Short % of Float | 4.61% |
| Short Ratio (days to cover) | 1.09 |
Valuation Ratios
The PE ratio is -4.71 and the forward PE ratio is -1.5.
| PE Ratio | -4.71 |
| Forward PE | -1.5 |
| PS Ratio | 26.59 |
| Forward PS | 91.9 |
| PB Ratio | 4.48 |
| P/FCF Ratio | -5.23 |
| PEG Ratio | n/a |
Enterprise Valuation
Aligos Therapeutics Inc. has an Enterprise Value (EV) of -81.97M.
| EV / Earnings | 0.93 |
| EV / Sales | -5.28 |
| EV / EBITDA | 0.96 |
| EV / EBIT | 0.93 |
| EV / FCF | 1.04 |
Financial Position
The company has a current ratio of 5.9, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.9 |
| Quick Ratio | 5.9 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 3.4 |
| Cash Flow / Debt | -24.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.95% and return on capital (ROIC) is -86.16%.
| Return on Equity (ROE) | -0.95% |
| Return on Assets (ROA) | -0.58% |
| Return on Capital (ROIC) | -86.16% |
| Revenue Per Employee | 228.37K |
| Profits Per Employee | -1.29M |
| Employee Count | 68 |
| Asset Turnover | 0.1 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 795.00K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by 133.36% in the last 52 weeks. The beta is 2.12, so Aligos Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.12 |
| 52-Week Price Change | 133.36% |
| 50-Day Moving Average | 15.26 |
| 200-Day Moving Average | 15.91 |
| Relative Strength Index (RSI) | 78.88 |
| Average Volume (20 Days) | 327.88K |
Income Statement
In the last 12 months, Aligos Therapeutics had revenue of $15.53M and earned -$87.68M in profits. Earnings per share was $-3.52.
| Revenue | 15.53M |
| Gross Profit | 12.46M |
| Operating Income | -88.13M |
| Net Income | -87.68M |
| EBITDA | -85.06M |
| EBIT | -88.13M |
| Earnings Per Share (EPS) | -3.52 |
Balance Sheet
The company has $135.70M in cash and $11.14M in debt, giving a net cash position of $124.57M.
| Cash & Cash Equivalents | 135.70M |
| Total Debt | 11.14M |
| Net Cash | 124.57M |
| Retained Earnings | -486.80M |
| Total Assets | 88.43M |
| Working Capital | 58.87M |
Cash Flow
In the last 12 months, operating cash flow was -$79.00M and capital expenditures -$19.00K, giving a free cash flow of -$79.02M.
| Operating Cash Flow | -79.00M |
| Capital Expenditures | -19.00K |
| Free Cash Flow | -79.02M |
| FCF Per Share | -3.18 |
Margins
Gross margin is 80.24%, with operating and profit margins of -567.5% and -564.61%.
| Gross Margin | 80.24% |
| Operating Margin | -567.5% |
| Pretax Margin | -559.5% |
| Profit Margin | -564.61% |
| EBITDA Margin | -547.74% |
| EBIT Margin | -567.5% |
| FCF Margin | -508.83% |
Dividends & Yields
ALGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.31% |
| FCF Yield | -64.51% |
Analyst Forecast
The average price target for ALGS is $75, which is 119.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $75 |
| Price Target Difference | 119.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Aug 19, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Aug 19, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -9.4 |
| Piotroski F-Score | 3 |